FFL Partners announced that it has completed a growth investment in Johnson County Clin-Trials (JCCT).
According to data captured in the LevinPro HC database, this transaction represents the 20th clinical trials acquisition of 2023. Financial terms of the private transaction were not disclosed.
JCCT is a clinical research site platform serving pharmaceutical and biotechnology companies and contract research organizations. Headquartered in Lenexa, Kansas, JCCT specializes in Phase I – IV clinical trials, encompassing both healthy volunteers and special populations. Since its inception in 2005, the company has concluded approximately 300 clinical trials, engaging more than 15,000 study participants.
Founded in 1997, FFL Partners is a San Francisco-based private equity firm with more than $5 billion under management. FFL invests in middle-market companies with growth potential. It generally commits $50 million to $300 million to individual transactions out of a $2 billion fund raised in 2015.
